associated with a polarized T H 2 response (6), the response to hookworm has been reported as a mixed T H 1/T H 2 response (26, 27) . Hookworm and A. lumbricoides also have differing effects on other diseases, such as malaria (10) . Thus, the response to A. lumbricoides may be more favorable to conception and implantation, because it more closely resembles the immunological state in pregnancy and less closely resembles proinflammatory states that suppress fecundity. Second, hookworm infection may be more costly than A. lumbricoides infection, such that the costs imposed by infection, such as anemia and nutritional loss, outweigh any effect of immune modulation. Although we do not have direct measures of parasite load, hookworm is associated with both lower BMI and lower hemoglobin for women in our sample, whereas A. lumbricoides is not. Future studies will need to investigate the importance of parasite burden in these associations.
Although consistent with our hypothesis, it is still unexpected to see positive associations between fecundity and A. lumbricoides infection, given that most parasites decrease reproduction. However, this association might instead be understood not as de novo increases in fecundity, but as the suppression of responses that would otherwise decrease fecundity. For example, most organisms down-regulate reproductive effort during acute illness because inflammation suppresses reproductive function (28) . If A. lumbricoides infection modulates inflammatory responses, then it might also limit inflammation-induced reproductive suppression, as well as sickness behavior and associated reductions in sexual activity (29, 30) . If so, then the effects of A. lumbricoides might only be observed in the presence of other illnesses or conditions resulting in excess inflammation. An additional possibility is that the increase in fertility represents fecundity compensation, a host response in which reproductive effort is shifted toward earlier ages to compensate for increasing morbidity or mortality (15) . However, our analysis cannot fully evaluate these kinds of lifetime or cumulative effects, because our longitudinal sample remains short relative to the human life span.
Regardless of mechanism, these results indicate that across populations, helminths may have unappreciated effects on demographic patterns, particularly given their high global prevalences (5 
CANCER IMMUNOLOGY
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Cécile Delarasse, 24 Valérie Boige, 18, 25 Michel Ducreux, 8, 25 Suzette Delaloge, 16, 26 Christophe Borg, 27 Fabrice André, 1, 16, 28, 29 Giovanna Schiavoni, 13 Ilio Vitale, Antitumor immunity driven by intratumoral dendritic cells contributes to the efficacy of anthracycline-based chemotherapy in cancer. We identified a loss-of-function allele of the gene coding for formyl peptide receptor 1 (FPR1) that was associated with poor metastasis-free and overall survival in breast and colorectal cancer patients receiving adjuvant chemotherapy. The therapeutic effects of anthracyclines were abrogated in tumor-bearing Fpr1 −/− mice due to impaired antitumor immunity. Fpr1-deficient dendritic cells failed to approach dying cancer cells and, as a result, could not elicit antitumor T cell immunity. Experiments performed in a microfluidic device confirmed that FPR1 and its ligand, annexin-1, promoted stable interactions between dying cancer cells and human or murine leukocytes. Altogether, these results highlight the importance of FPR1 in chemotherapy-induced anticancer immune responses.
T he success of anticancer chemotherapy is linked to a durable tumor-targeting immune response (1) . Accordingly, the presence of tumor-infiltrating dendritic cells (DCs) and CD8
+ T lymphocytes at diagnosis increases the likelihood of breast cancer patients responding to anthracyclines (2-6). One mechanism through which anthracyclines can stimulate an antitumor immunity is by inducing immunogenic cell death (ICD), and this mechanism implies signaling through innate immune receptors including Toll-like receptors 3 (TLR3) and 4 (TLR4) (7) (8) (9) (10) . We designed a screen for identifying candidate genetic defects that negatively affect chemotherapeutic responses. To this aim, we identified 328 nonsynonymous single-nucleotide polymorphisms (SNPs) affecting proteins involved in the recognition of dying cells by innate immune effectors (11) or influencing the incidence or prognosis of major human cancers and occurring in Caucasians with an allelic frequency >5% (table S1). DNA samples from breast cancer patients treated with adjuvant anthracycline-based chemotherapy (belonging to two independent cohorts) (table S2 and S3) were genotyped, and the effect of each SNP on overall survival (OS) was determined. When a dominant genetic model was applied, only one SNP was significantly (raw P < 0.05) associated with OS independent of major clinicopathological variables in both patient cohorts: rs867228 (fig. S1A, C to H). This SNP (1037A>C) affects exon 2 of the gene coding for formyl peptide receptor 1 (FPR1), which promotes the chemotactic interaction of neutrophils with necrotic hepatocytes (12, 13) . rs867228 provokes an amino acid substitution (Glu 346 Ala) that suppresses FPR1 signaling (14, 15) . Other SNPs with less drastic effects on FPR1 function (15, 16) had no effect on OS ( fig. S1B and  fig. S2 , A to C). As opposed to patients bearing the most frequent FPR1 allele (17) Immunofluorescence stainings were performed on tumors recovered 2 days after chemotherapy. Quantitative analysis (E) of the immunostainings [(F) and (G)] are shown. In (E), the length/width ratio (elongation) was determined in 60 to 100 randomly chosen cells, using the morphometric methods illustrated in (F) and (G). Box plots report the lower and upper quartile plus the median value. ns, not significant; ***P < 0. (iii) N-formylated peptides contained in bacteria and mitochondria (22) ; and (iv) annexin A1 (ANXA1), a ubiquitously expressed cytosolic protein (23) . Knocking out the genes coding for Ctsg ( fig. S4D), Fam19a4 (fig. S4E ), or mitochondrial methionyl-tRNA formyltransferase (Mtfmt), an enzyme that catalyzes formylation reactions in mitochondria (24) ( fig. S4B ), had no effect on the capacity of MCA205 cells to elicit anticancer immune responses upon exposure to anthracyclines in vitro and to respond to mitoxantrone and doxorubicin in vivo (Fig. 2, E and F; fig. S5, C and D 
Ly6G
-and Ly6G + cells after chemotherapy in vivo (Fig. 3B and fig. S13, A to D) . Moreover, Fpr1 expression levels increased in bone marrow-derived DC confronted with dying (but not living) cancer cells in vitro ( fig. S13 , E to G). Ly6C high
-cells do (whereas Ly6G + cells do not) contribute to the efficacy of anthracyclinebased chemotherapy (26) . Our results therefore suggest the importance of FPR1 expression in the Ly6C high Ly6G -myeloid cell population, which comprises DCs and their precursors (26) . Elevated expression of the human orthologs of all immune-relevant genes influenced by Fpr1 in mice (Fig. 3A) had a significant (P < 0.05) positive effect on the response of breast cancer patients to anthracyclines in four out of five cohorts studied (Fig. 3D) , suggesting that these genes are clinically relevant. Moreover, the mutational status of FPR1 influenced the expression level of several genes involved in antigen presentation within neoplastic lesions of breast cancer patients ( fig. S14) .
The presence or absence of Anxa1 (in tumor cells) or that of Fpr1 (in the host) did not affect the capacity of chemotherapy to elicit autophagy, apoptosis, and necrosis in cancer cells ( fig. S15) . Moreover, the absence of Fpr1 in the host did not influence the density of tumor infiltration by CD11c + CD86 + DCs, macrophages, or granulocytes after chemotherapy ( fig. S16A ). Morphometric analyses of the ratio between the maximum length and the perpendicular width of tumorinfiltrating myeloid cells, reflecting cellular asymmetry related to migration (27) , revealed a selective defect in the chemotherapy-induced elongation of intratumoral DCs (but not macrophages and granulocytes) in Fpr1 −/− hosts (Fig. 3 , E to G, and figs. S16B and S17). Two days after chemotherapy, a sizeable fraction of cancer cells underwent apoptosis and hence contained immunofluorescence microscopy-detectable active caspase 3 (Casp3a + DCs infiltrating tumors treated with anthracyclines in Fpr1 −/− hosts (Fig. 3, H to J ). In accord with its expression pattern (Fig. 3B) , Fpr1 did not influence the DCPI of macrophages, yet affected that of neutrophils ( fig. S17D) 
cells (which include inflammatory DCs) (28) to acquire antigens from cancers engineered to express green fluorescent protein (GFP) tethered to the inner leaflet of the plasma membrane, in response to chemotherapy (Fig. 4, A and B, and fig. S18A ). Moreover, Fpr1 inhibition interfered with the capacity of tumor-infiltrating CD11b + Ly6C high Ly6G -cells to express increased levels of class II major histocompatibility complex (MHC) proteins (I-A/ I-E) upon chemotherapy in vivo (Fig. 4, A and B, and  fig. S18B ). However, Fpr1 knockout did not affect major DC functions in vitro and did not interfere with the presentation of soluble protein antigen by DC (figs. S19 and S20).
The failure of Fpr1 −/− DCs to encounter dying cancer cells and to take up tumor antigens should compromise T cell responses. Accordingly, the capacity of chemotherapy to stimulate the intratumoral proliferation of adoptively transferred T cells specific for a model antigen [ovalbumin (OVA)] was attenuated in Fpr1 −/− mice harboring OVAexpressing MCA205 tumors, as compared with WT mice (fig. S21A ). WT DCs purified from OVAexpressing tumors after chemotherapy stimulated OT1 responses upon their adoptive transfer into naïve mice, whereas Fpr1 −/− DCs failed to do so ( fig. S21, B and C) . Moreover, the frequency of tumor-infiltrating CD3 + T cells was increased by anthracycline-based chemotherapy in WT mice but less so in Fpr1 −/− hosts (Fig. 4, C and D) . The aforementioned results suggest that the initial defect of the Fpr1 −/− immune system consists in the failure of DCs to migrate toward dying cancer cells. We attempted to explore this hypothesis in vitro. When mouse splenocytes or human peripheral blood mononuclear cells (PBMCs) expressing functional FPR1 (WT for mice, FPR1
CC for humans) were confronted with anthracyclinetreated WT cancer cells in a microfluidic device (29) , they migrated toward dying or dead cells treated with doxorubicin (but not to live untreated cells), and the fraction of leukocytes containing DCs exhibited a prolonged (>60 min) juxtaposition with the corpses (Fig. 4, E and F, and fig.  S22A ). Conversely, FPR1-deficient cells (Fpr1
CA or FPR1 AA for humans) were largely unable to engage in such long-term interactions. Moreover, no stable conjugates were formed between DCs and dying or dead Anxa1 −/− cancer cells (Fig. 4, E to J; fig. S22, A and B; fig.  S23 , A to C; and movies S1 to S24). Prolonged interactions of dying cancer cells with human blood-borne DCs were observed, but only if such DCs expressed functional FPR1 ( fig. S22, C and D) .
Altogether, our findings underscore the obligate contribution of the interaction between ANXA1 and FPR1 to the immune response against cancer cells succumbing to chemotherapy. Although it does not influence the recruitment of inflammatory DCs (with a CD11c + CD86 + Ly6C high phenotype) to the tumor bed (which depends on other factors, including ATP and chemokines) (26, 28) , FPR1 is required for DCs to come into close proximity of dying cancer cells, to establish stable contacts with corpses, to take up tumorassociated antigens, and to cross-present them to T cells. Hence, deficient FPR1 signaling results in defective intratumoral DC maturation and insufficient T cell-mediated anticancer immune responses, ultimately abolishing the efficacy of chemotherapy. Given the high allelic frequency of the loss-of-function FPR1 SNP rs867228 (17) , it will be important to identify means for restoring or bypassing defective FPR1 signaling. Figs. S1 to S23 Tables S1 to S11 Movies S1 to S24 References (30- Transcription factors (TFs) bind specific sequences in promoter-proximal and -distal DNA elements to regulate gene transcription. RNA is transcribed from both of these DNA elements, and some DNA binding TFs bind RNA. Hence, RNA transcribed from regulatory elements may contribute to stable TF occupancy at these sites. We show that the ubiquitously expressed TF Yin-Yang 1 (YY1) binds to both gene regulatory elements and their associated RNA species across the entire genome. Reduced transcription of regulatory elements diminishes YY1 occupancy, whereas artificial tethering of RNA enhances YY1 occupancy at these elements. We propose that RNA makes a modest but important contribution to the maintenance of certain TFs at gene regulatory elements and suggest that transcription of regulatory elements produces a positive-feedback loop that contributes to the stability of gene expression programs.
A ctive promoter and enhancer elements are transcribed bidirectionally (Fig. 1A) (1-3) . Although various models have been proposed for the roles of RNA species produced from these regulatory elements, their functions are not fully understood (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . Evidence that some DNA binding transcription factors (TFs) also bind RNA (14, 15) led us to consider the possibility that there might be a direct and general role for promoter-proximal and -distal enhancer RNA in the binding and maintenance of TFs at regulatory elements.
We used global run-on sequencing (GRO-seq) to sequence nascent transcripts in murine embryonic stem cells (ESCs) at great depth, which confirmed that active promoter and enhancer elements are generally transcribed bidirectionally (Fig. 1B, fig. S1A , and table S1) (see also supplementary materials and methods). We then focused our studies on the TF Yin-Yang 1 (YY1), because it is ubiquitously expressed in mammalian cells, plays key roles in normal development, and can bind RNA species in vitro (15, 16) . Chromatin immunoprecipitation sequencing (ChIP-seq) analysis in ESCs revealed that YY1 binds to both active enhancers and promoters, with some preference for promoters (Fig. 1, C and  D, fig. S1 , and table S2). In contrast, the pluripotency TF OCT4 preferentially occupies enhancers ( fig. S1B ). Consistent with this, YY1 sequence motifs were enriched at promoters, whereas OCT4 motifs were enriched at enhancers ( fig. S1B ). Neither YY1 nor OCT4 occupied the promoterproximal sequences of inactive genes ( fig. S2 ). These results establish that YY1 generally occupies active enhancer and promoter-proximal elements in ESCs.
We next used cross-linking immunoprecipitation sequencing (CLIP-seq) in ESCs to investigate YY1 binding to RNA in vivo (figs. S3 and S4 and table S3). Our results showed that YY1 binds RNA species at the active enhancer and promoter regions where it is bound to DNA (Fig. 1, C  and D, and fig. S1C ). At promoters, YY1 preferentially occupied RNA downstream rather than upstream of transcription start sites ( fig. S1B) , consistent with YY1 motif distribution and evidence that upstream noncoding RNA is unstable (3, 17, 18) . In similar experiments with OCT4, substantial levels of RNA binding were not observed ( fig. S5 ). These results suggest that YY1 generally binds to RNA species transcribed from enhancers and promoters in vivo.
The DNA and RNA binding properties of YY1 were further investigated in vitro (Fig. 2 and figs. S6 to S8). The recombinant YY1 protein bound both DNA and RNA probes in electrophoretic mobility shift assays (EMSA), showing greater affinity for DNA than for RNA. The affinity of YY1 varied for different RNA sequences (fig. S8) . The four YY1 zinc fingers can bind DNA (19) , but the portion of YY1 that interacts with RNA is unknown. The zinc finger-containing C-terminal region and the N-terminal region of YY1 were purified, and their DNA and RNA binding properties were further investigated ( fig. S9) . The zinc finger region of YY1 bound to DNA but not to RNA, whereas the N-terminal region of YY1 bound to RNA (fig. S9) . Furthermore, the DNA probe did not compete efficiently with the RNA probe for YY1 binding (figs. S7C and S8C). These results suggest that different regions of YY1 are responsible for binding to DNA and RNA.
The observation that YY1 binds to enhancer and promoter-proximal elements and to RNA transcribed from those regions led us to postulate that nascent RNA contributes to stable TF occupancy at these regulatory elements (Fig. 3A) . If this model is correct, then reduced levels of nascent RNA at promoters and enhancers might lead to reduced YY1 occupancy at these sites. We briefly inhibited transcription elongation with the reversible inhibitor D-rybofuranosylbenzimidazole (DRB) to reduce RNA levels at promoters and enhancers without causing changes in the steady-state levels of YY1 (figs. S10 and S11). DRB treatment reduced transcription at promoters and enhancers, which caused a small but significant decrease in the levels of YY1 at these regions ( fig. S10 ). Super-enhancers are clusters of enhancers that are highly transcribed (20) , and DRB treatment had a profound effect on transcription at these sites ( fig. S10) . Similar results were observed with additional inhibitors ( fig. S10 ). When transcription was allowed to resume after DRB removal, the levels of YY1 increased at promoters and enhancers (Fig.  3B and fig. S10A ). These results suggest that nascent RNA produced at promoters and enhancers contributes to YY1 binding to these elements.
The exosome reduces the levels of enhancer RNAs once they are released from RNA polymerase II (degradation is 3′ to 5′) (21) , so knockdown of an exosome component will cause an increase in untethered enhancer RNA, which might titrate some YY1 away from enhancers. Indeed, exosome knockdown led to increased steady-state levels of enhancer RNAs and a decrease in the levels of YY1 bound to enhancers (Fig. 3C and fig. S12 ). These results are consistent with the model that YY1 binding to DNA is stabilized by binding to nascent RNA.
If YY1 binding to DNA is stabilized by its binding to RNA, then ribonuclease (RNase) treatment of chromatin should reduce YY1 occupancy. Chromatin was extracted from ESC nuclei, and
